Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2020-08-13 Regulatory Filings
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates announces its third clinical routine customer in Spain
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the adoption of a medical product (suPARnostic) by a hospital in Spain. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it report on dividends, share changes, or governance. As it is a general corporate announcement regarding business operations and product implementation that does not fall into a specific specialized category, it is classified as a general regulatory filing/announcement.
2020-08-13 English
ViroGates announces its third clinical routine customer in Spain
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a new clinical customer for ViroGates' medical technology. It does not fit into specific financial reporting categories like 10-K, IR, or ER. It is a general corporate update regarding business operations and customer acquisition. Since it is a standard regulatory announcement that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2020-08-13 English
ViroGates announces its Interim Report for Q2, 2020 - New clinical routine customers and an increasing number of orders
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, Q2 2020' and contains comprehensive financial statements (Income Statement, Balance Sheet), management review, and board statements for a specific fiscal period (Q2 2020). It provides substantive financial data and analysis, meeting the criteria for an Interim/Quarterly Report (IR) rather than a mere announcement or summary. Q2 2020
2020-08-13 English
ViroGates announces its Interim Report for Q2, 2020 - New clinical routine customers and an increasing number of orders
Report Publication Announcement Classification · 95% confidence The document is a company announcement titled 'ViroGates announces its Interim Report for Q2, 2020'. It provides a summary of financial highlights and business updates but explicitly states in the text that it is a summary to be read in conjunction with the full Interim Report, which is provided as an attachment (20200813 Interim Report O2 2020.pdf). Following the 'Menu vs Meal' rule, since this is an announcement of a report rather than the full report itself, it is classified as a Report Publication Announcement.
2020-08-13 English
ViroGates announces a capital increase in connection with the exercise of warrants
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of warrants. It details the number of new shares issued, the exercise price, the impact on total share capital, and the listing of these new shares. This falls directly under the definition of a share issue or capital change announcement.
2020-06-26 English
ViroGates announces a capital increase in connection with the exercise of warrants
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement from ViroGates regarding a capital increase resulting from the exercise of warrants. It details the number of new shares issued, the exercise price, and the resulting change in total share capital. This falls directly under the definition of a share issue or capital change announcement.
2020-06-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.